A phase I study of NK105 administrated weekly in patients with advanced solid malignancies.
Phase 1
- Conditions
- advanced solid malignancies
- Registration Number
- JPRN-jRCT2080221196
- Lead Sponsor
- ippon Kayaku Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 25
Inclusion Criteria
Histologically or cytologically confirmed malignant solid tumour.
Refractory to standard therapy or for which no suitable effective standard therapy exists.
Exclusion Criteria
Treated with taxanes within 6 months
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method